Hauttumore | ICD10: C43, C44, D03, D04
Sie befinden sich hier:
Bei allen Anfragen zu den Studien nehmen Sie bitte Kontakt mit der Cancer Hotline des CCCC auf.
Studien offen zur Rekrutierung
ADMEC-O CA184-205137 kB
Prospective Randomized Trial of an Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma (MCC) With 3 mg/kg BW Ipilimumab (Yervoy®) Every 3 Weeks for 12 Weeks Versus Observation
AMGEN MASTERKEY-265_Talimogene Laherparepvec131 kB
A Phase 1b/3, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresected, Stage IIIB to IVM1c Melanoma
BMS NivoPass_CA209-23471 kB
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
COMBI-r266 kB
Beobachtungsstudie zu Sicherheit und Effizienz von Dabrafenib und Trametinib im klinischen Alltag (COMBI-r)
CURVAC_CV-8102-00898 kB
Phase I Study of Intratumoral CV8102 in Patients With Advanced Melanoma, Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma of the Head and Neck, or Adenoid Cystic Carcinoma
Dynavax DV3-MEL-01_Keynote 184240 kB
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
EORTC Studie 1208 Minitub121 kB
Minitub: Prospective Registry of Sentinel Node (SN) Positive Melanoma Patients With Minimal SN Tumor Burden Who Undergo Completion Lymph Node Dissection (CLND) or Nodal Observation
FUSI-ProjektExpression of PDL1 and other relevant immune-checkpoints on CTCs and matched tissues in patients with metastatic melanoma
Galderma56 kB
A randomized, double-blind, multi-centre, placebo-controlled, parallel-arm phase 2 trial to assess safety, efficacy and pharmacokinetics of CD11301 0.03% and 0.06% gel in the treatment of Cutaneous T-Cell Lymphoma (CTCL), stages IA, IB and IIA
IMCgp100-201106 kB
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients with Advanced Melanoma
IMMUNED135 kB
A Phase II Randomized, Double-Blind Trial of Immunotherapy with Nivolumab or Nivolumab plus Ipilimumab versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanoma with No Evidence of Disease - IMMUNED
ImmunoCobiVem156 kB
Bestimmung der Wirksamkeit und Sicherheit von Cobimetinib plus Vemurafenib gefolgt von dem PDL1-Antikörper Atezolizumab bei Patienten mit inoperablem oder metastasiertem Melanom mit BRAFV600 Mutation.
NICCI StudieA Phase II, single-armed, multicenter Trial of neoadjuvant vismodegib in patients with large and/or recurrent basal cell carcinoma (NICCI)
PH-L19IL2TNF-02/15267 kB
A pivotal Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment followed by surgery versus surgery alone in clinical stage III B/C melanoma patients
PV-10-MM-31_ Intralesional Injection267 kB
PV-10 Intralesional Injection vs Systemic Chemotherapy or Intralesional OncolyticViral Therapy for Treatment of Locally Advanced Cutaneous Melanoma without Distant Metastases
Regeneron143 kB
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma
RESMAIN Studie152 kB
A Multicentre, Double Blind, Randomised, Placebo-controlled, Phase II Trial to Evaluate Resminostat for Maintenance Treatment of Patients With Advanced Stage (Stage IIB-IVB) Mycosis Fungoides (MF) or Sézary Syndrome (SS) That Have Achieved Disease Control With Systemic Therapy - the RESMAIN Study
Roche coveNISEine nicht-interventionelle Studie zur Untersuchung der Sicherheit, Wirksamkeit und Anwendung von Cobimetinib und Vemurafenib bei Patienten mit BRAF-V600-MutationPositivem Melanom mit und ohne Hirnmetastasen in der alltäglichen Praxis. (ML 39302)
SVM9122A single-centre, single arm, open-label, exploratory trial of Interleukin-2 administered subcutaneously as neo-adjuvant treatment prior to sentinel lymph node biopsy(SLNB)/complete lymph node dissection (CLND) in subjects with stage III malignant melanom
TREAT20plusValidation of the virtual patient to optimise individual therapy for patients with metastatic melanoma
Xenograft_HTCCSammlung von MM-Filiae zur Eablierung von Xenografts